Skip to main content

isolated Antibody drug conjugates (ADCs)

Love Employee

Pfizer’s (NYSE:PFE) acquisition of Seagen (NASDAQ:SGEN), announced in March, is expected to complement the pharma giant’s current portfolio of oncology therapies.

Seagen focuses on antibody-drug conjugates (ADCs), a technology that the company says can “harness the targeting power of antibodies

Read the original article

Leave a Reply